Skip to main content Skip to section navigation Skip to footer
Product Indications Back to Viveve.com

Product Indications

VIVEVE®️ SYSTEM
In the United States the Viveve System is cleared by the FDA for general surgery procedures for electrocoagulation and hemostasis.

The Viveve System has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan and China. International approvals and clearances include vaginal laxity and/or improvement of sexual function indications. In Argentina improvement of urinary incontinence in women is also an approved indication.
Viveve Medical, Inc.
Investor Relations
  • Investors
  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Leadership Team
    • Clinical Advisory Board
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
    • Board Diversity Matrix
  • Back to Viveve.com

Press Releases

News & Events

News & Events

  • Overview
  • Press Releases
  • Publications
  • IR Calendar
  • Analyst Coverage
  • Email Alerts
Jan 17, 2023 6:30am EST

Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence

Dec 15, 2022 8:28am EST

Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded

Dec 01, 2022 8:28am EST

Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Nov 10, 2022 4:02pm EST

Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 27, 2022 8:28am EDT

Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022

Oct 04, 2022 8:28am EDT

Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence

Sep 27, 2022 8:28am EDT

Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout

Sep 22, 2022 8:28am EDT

Viveve to Participate in Ladenburg Thalmann Healthcare Conference

Sep 15, 2022 8:28am EDT

Viveve to Participate in Alliance Global Partners Virtual MedTech Conference

Sep 01, 2022 8:28am EDT

Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 35
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
logo

A Women’s Health Company Focused on the Treatment of Female Stress Urinary Incontinence

Viveve®️ System

In the United States the Viveve System is cleared by the FDA for general surgery procedures for electrocoagulation and hemostasis.

The Viveve System has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan and China. International approvals and clearances include vaginal laxity and/or improvement of sexual function indications. In Argentina improvement of urinary incontinence in women is also an approved indication.

Contact Viveve

Viveve Medical, Inc.
345 Inverness Drive South
Building B, Suite 250
Englewood, CO 80112
ir@viveve.com

Facebook LinkedIn Instagram
©2023 Viveve Medical, Inc. All Rights Reserved. Viveve is a registered trademark of Viveve, Inc.
Terms of Use Privacy Policy Disclaimer Sitemap